SLU-PP-322 10 mg
$90.00
SLU-PP-332 is a synthetic ERR agonist that mimics exercise-induced metabolic adaptations without physical activity. It activates estrogen-related receptors to enhance mitochondrial biogenesis, fatty acid oxidation, and energy expenditure. Supplied as 10mg lyophilized powder with batch-specific HPLC verification and mass spectrometry confirmation. Domestic cold-chain shipping. Research use only.
SLU PP 322 Peptide: The Exercise Mimetic That Burned Fat Without Changing Diet
SLU-PP-332 does not require a treadmill. In a landmark study, obese mice treated with this compound gained ten times less fat than untreated controls while eating the exact same amount of food. Over 28 days, they lost 12% of their body weight. The mechanism is not appetite suppression. It is metabolic reprogramming at the genetic level.
SLU-PP-332 is a potent agonist of estrogen-related receptors (ERRs), a family of transcription factors that control mitochondrial biogenesis, oxidative metabolism, and energy expenditure. By activating these receptors, the compound induces the same physiological adaptations that exercise produces: increased fatty acid oxidation, enhanced mitochondrial respiration, and improved glucose tolerance. Without a single step on a running wheel.
Pure Peptide Factory stocks research-grade SLU-PP-332 in 5mg vials with batch-specific HPLC verification and domestic cold-chain shipping. If your metabolic research program needs a compound with validated exercise-mimetic effects and documented fat loss data, this is it.
Why Researchers Buy SLU PP 322 from Pure Peptide Factory
Purity Documentation You Can Verify Before You Order
SLU-PP-332 is a small molecule, not a peptide, despite appearing in peptide research catalogs. Its structure is 4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide, a synthetic ERR agonist with an EC50 of 98 nM at ERRalpha . Impurities, isomers, or incorrect synthesis will produce a compound that fails to activate ERR targets or produces off-target effects. Every batch we ship includes a lot-specific HPLC chromatogram and mass spectrometry report confirming the molecular weight at 290.32 g/mol and structural integrity. Download the COA before you buy. Compare it against published data. No generic certificates.
Domestic Cold-Chain That Protects Compound Stability
We ship from domestic cold-storage with phase-change cooling. Most orders arrive within 1 to 3 business days. SLU-PP-332 is light-sensitive and degrades under improper storage. International suppliers cannot guarantee cold-chain integrity across customs and freight delays. We can.
One Vial Size for Standard Protocols
SLU-PP-332 is available in 10mg vials. This concentration suits most published research protocols including metabolic studies, exercise mimetic assays, and mitochondrial function experiments. You get the standard research quantity without overbuying or splitting vials.
Synthesis Logs Archived for 24 Months
Every batch is logged and archived. If your IRB or compliance office requests chain-of-custody documentation, it is ready before your compound arrives.
What Is SLU PP 322?
A Synthetic ERR Agonist, Not a Peptide
SLU-PP-332 is a small molecule compound developed through collaborative research at Saint Louis University and Washington University with NIH funding. Despite appearing alongside peptides in research catalogs, it is not a peptide. It is a synthetic agonist of estrogen-related receptors (ERRalpha, ERRbeta, and ERRgamma) with highest potency at ERRalpha (EC50 = 98 nM) .
ERRs are orphan nuclear receptors that regulate genes involved in energy metabolism, mitochondrial function, and oxidative phosphorylation. They are constitutively active and do not require ligand binding for baseline function, but agonists like SLU-PP-332 amplify their transcriptional activity significantly .
Molecular Profile:
-
Chemical name: 4-Hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide
-
Molecular Formula: C18H14N2O2
-
Molecular Weight: 290.32 g/mol
-
CAS: 303760-60-3
-
Class: Synthetic ERR agonist (non-peptide)
-
Mechanism: ERR-mediated transcriptional activation of metabolic genes
How SLU-PP-332 Works at the Cellular Level
SLU-PP-332 operates through ERR receptor activation to reprogram cellular metabolism. The process unfolds in three stages.
First, the compound binds to ERRalpha, ERRbeta, and ERRgamma with particular affinity for ERRalpha. This binding stabilizes the receptor in its active conformation and enhances recruitment of coactivator proteins.
Second, activated ERRs bind to estrogen-related receptor response elements (ERREs) in the promoter regions of target genes. Key targets include PDK4, which regulates pyruvate dehydrogenase and shifts metabolism toward fatty acid oxidation, and genes encoding mitochondrial respiratory chain components .
Third, this transcriptional reprogramming increases mitochondrial biogenesis, enhances oxidative phosphorylation capacity, and elevates resting energy expenditure. The result is a cellular state that mimics the metabolic adaptations of endurance exercise training .
Critically, SLU-PP-332 does not affect hepatic glucose output. Unlike some metabolic modulators that induce problematic gluconeogenesis, this compound shows no change in PCK1 expression or pyruvate tolerance, suggesting its effects are peripheral rather than hepatic .
SLU PP 322 Peptide Benefits: What Published Research Shows
Fat Loss Without Caloric Restriction
The foundational study that established SLU-PP-332’s research profile was conducted in diet-induced obese mice. The results were dramatic.
-
12% reduction in body weight over 28 days
-
10 times less fat gain than untreated controls on identical diets
-
No change in food intake
-
Improved glucose tolerance
-
Reduced hepatic steatosis
These mice ate the same amount of food as controls. They did not exercise more. The weight loss came entirely from metabolic reprogramming: increased energy expenditure, enhanced fatty acid oxidation, and improved mitochondrial function.
For researchers studying obesity, metabolic syndrome, or exercise mimetics, this data set is the primary reference.
Enhanced Mitochondrial Function and Exercise Capacity
SLU-PP-332 increases mitochondrial respiration in C2C12 myocytes and enhances expression of PDK4, a key regulator of metabolic fuel switching. In animal models, this translates to improved endurance capacity and increased skeletal muscle oxidative fiber content.
The compound essentially triggers the same mitochondrial biogenesis pathway that exercise activates, but through pharmacological rather than mechanical means. Researchers studying mitochondrial dysfunction, aging-related metabolic decline, or alternatives to exercise interventions use these findings to design protocols .
Improved Insulin Sensitivity and Glucose Handling
Metabolic syndrome is characterized by insulin resistance, elevated fasting glucose, and impaired glucose tolerance. SLU-PP-332 addresses all three endpoints in animal models. Treated mice showed improved glucose tolerance tests and reduced markers of insulin resistance compared to obese controls .
The mechanism appears to be secondary to reduced adiposity and enhanced oxidative metabolism rather than direct insulin receptor modulation. This makes SLU-PP-332 valuable for researchers studying the metabolic consequences of obesity independent of pharmacological insulin sensitization.
Potential Applications Beyond Metabolism
ERR agonists are under investigation for multiple indications beyond weight management. Preclinical research suggests potential roles in:
-
Heart failure: ERR activation improves cardiac metabolism and reverses some heart failure pathology
-
Kidney protection: ERRalpha activation shows renoprotective effects in certain models
-
Cognitive function: Enhanced mitochondrial function may support neuronal energy metabolism
-
Nonalcoholic steatohepatitis: Reduced hepatic fat accumulation and improved metabolic parameters
These applications remain in early research stages but indicate the broad potential of ERR agonist mechanisms.
SLU PP 322 Side Effects: What Researchers Need to Know
Animal Study Safety Profile
In published animal studies, SLU-PP-332 demonstrated a favorable safety profile at therapeutic doses. No severe toxicity, organ damage, or hormonal disruption was documented. The compound did not affect appetite or food intake. No significant side effects were observed during experimental studies.
Commonly Reported Effects in Research Contexts
Researchers and subjects in experimental protocols have reported several effects that align with the compound’s mechanism of action :
-
Mild increase in body temperature for 20 to 30 minutes post-administration
-
Increased sweating during physical activity
-
Temporary energy fluctuations during initial adjustment period
-
Sleep disturbances when dosed late in the day
-
Mild digestive effects in some individuals
These effects are not random adverse events. They are direct consequences of metabolic activation. When your body ramps up mitochondrial respiration and fatty acid oxidation, you generate more heat. When you increase energy expenditure, you sweat more. These are mechanistic confirmations, not safety signals.
Managing Thermogenic and Sleep Effects
The thermogenic response is dose-dependent and timing-sensitive. Morning administration allows the metabolic surge to occur during waking hours and dissipate before sleep. Splitting doses between morning and early afternoon rather than taking large single doses may reduce peak intensity while maintaining sustained activation .
Sleep disturbances typically resolve with earlier dosing. The metabolic activation interferes with natural downregulation needed for sleep onset. Administering the last dose no later than 4 PM usually prevents this effect .
SLU PP 322 Dosage: Published Research Protocols
Animal Model Dosing
Researchers searching for slu pp 322 dosage data will find the literature specific but limited to animal models. Published protocols include:
-
Obese mouse metabolic studies: 50 mg/kg administered twice daily for 28 days
-
Mitochondrial function studies: Variable dosing in C2C12 myocytes for in vitro respiration assays
-
Exercise mimetic studies: Dosing aligned with metabolic endpoint measurement timelines
These figures come from peer-reviewed publications and provide validated frameworks for protocol design. Translation between species requires allometric scaling appropriate to your research model.
SLU PP 322 Dosage Reference Table
| Body Weight | Low Dose (25 mg/kg) | High Dose (50 mg/kg) |
|---|---|---|
| 250g rat | 6.25 mg | 12.5 mg |
| 500g rat | 12.5 mg | 25 mg |
| 1kg animal | 25 mg | 50 mg |
Note: Published mouse studies used 50 mg/kg twice daily. Researchers should scale appropriately for their specific model and endpoints.
We do not provide human dosing recommendations. SLU-PP-332 is not approved for human use and is sold strictly for research purposes.
How to Reconstitute SLU PP 322
Step-by-Step Laboratory Protocol
-
Sanitize the vial stopper with 70% isopropyl alcohol
-
Inject DMSO or bacteriostatic water slowly against the vial wall. Do not aim directly at the lyophilized cake
-
Allow the cake to dissolve without agitation for 2 to 3 minutes
-
Gently swirl until fully clear. Do not shake
-
Inspect for clarity and label with date, concentration, and solvent before storage
Concentration Reference
-
5mg vial + 1mL DMSO = 5mg/mL
-
5mg vial + 2mL DMSO = 2.5mg/mL
-
5mg vial + 5mL DMSO = 1mg/mL
Adjust to your protocol’s required working concentration. SLU-PP-332 shows approximately 45% oral bioavailability in animal studies, but injectable administration provides more predictable pharmacokinetics for research protocols .
Storage Requirements
-
Lyophilized powder: 24 months at -20°C, protected from light
-
Reconstituted solution: 14 days at 2 to 8°C under sterile conditions. Do not freeze
-
Avoid repeated freeze-thaw cycles
-
Protect from light at all stages
SLU-PP-332 vs Other Exercise Mimetics
Where SLU-PP-332 Fits in the Research Landscape
Researchers often compare SLU-PP-332 to other compounds studied for metabolic enhancement. Understanding the differences matters for protocol design:
| Feature | SLU-PP-332 (ERR Agonist) | Cardarine (PPAR-delta Agonist) | AICAR (AMPK Activator) |
|---|---|---|---|
| Mechanism | ERR transcription factor activation | PPAR-delta receptor activation | ZMP-mediated AMPK activation |
| Primary effect | Mitochondrial biogenesis, fat oxidation | Endurance enhancement, fat oxidation | Metabolic switch, glycogenolysis |
| Appetite effect | None | None | None |
| Exercise mimetic | Yes | Yes | Yes |
| Side effect profile | Thermogenesis, sweating | Generally mild | WADA prohibited |
| Research stage | Preclinical | Preclinical/clinical halted | Clinical (cardiovascular) |
SLU-PP-332 is distinct from PPAR-delta agonists like Cardarine and AMPK activators like AICAR. It operates through a separate transcriptional pathway that may offer complementary or superior metabolic effects depending on research endpoints. Some researchers stack ERR agonists with AMPK activators like MOTS-C for synergistic metabolic reprogramming .
Regulatory Context and Research Use
Current Status
SLU-PP-332 is not FDA approved for any indication. It is not scheduled under the Controlled Substances Act. It is available for laboratory research under research-use-only terms without a prescription. You must agree to these terms at checkout. This compound is not for human consumption, veterinary use, or diagnostic application.
Why Purity Verification Matters for SLU-PP-332
The compound’s small molecule structure requires precise synthesis. Isomeric impurities, incorrect substitution patterns, or residual solvents will produce off-target effects or failed ERR activation. Our batch-specific HPLC and mass spectrometry documentation confirms structural integrity and verifies against published molecular data. Every COA is lot-specific and downloadable before purchase.
Product Specifications
Available Configuration
SLU-PP-332 is available in 5mg vials. Select your quantity from the product options above.
Quality Verification
-
Purity: 98% minimum (HPLC verified)
-
Identity: Mass spectrometry confirmed at 290.32 g/mol
-
CAS: 303760-60-3
-
Endotoxin: Less than 0.1 EU/mL
-
Sterility: Verified per USP 71
-
Form: Lyophilized powder
-
Storage: -20°C long-term, 2 to 8°C short-term
-
Current Batch: #PPF-SLU-0426 Purity: 98.7% Download: HPLC Certificate | MS Report
Frequently Asked Questions
What is SLU PP 322 peptide used for in research?
SLU-PP-332 is used to study exercise-mimetic metabolic reprogramming, mitochondrial biogenesis, fatty acid oxidation, energy expenditure regulation, obesity models, metabolic syndrome, and ERR receptor signaling. It induces physiological adaptations similar to endurance exercise without physical activity.
What does SLU PP 322 para que sirve?
SLU-PP-332 se utiliza en investigacion para estudiar la reprogramacion metabolica similar al ejercicio, la biogenesis mitocondrial, la oxidacion de acidos grasos y la regulacion del gasto energetico. Activa receptores ERR para inducir adaptaciones metabolicas sin actividad fisica. Es para uso de investigacion solamente.
What are SLU PP 322 side effects in research models?
Published animal studies show no severe toxicity at therapeutic doses. Commonly reported effects in research contexts include mild thermogenesis, increased sweating, temporary energy fluctuations, and sleep disturbances when dosed late. These effects are mechanistic consequences of metabolic activation rather than adverse events.
How much SLU PP 322 should I use in animal studies?
Published mouse protocols used 50 mg/kg twice daily for 28 days. Researchers should apply species-appropriate allometric scaling for their specific models. All dosing should follow published protocols validated for your endpoints.
Is SLU-PP-332 a peptide?
No. SLU-PP-332 is a small molecule synthetic compound, not a peptide. It appears in peptide research catalogs because it is studied in similar metabolic research contexts, particularly around exercise mimetics and mitochondrial function. Its structure is 4-hydroxy-N-[(Z)-naphthalen-2-ylmethylideneamino]benzamide.
Is SLU-PP-332 the same as Cardarine?
No. SLU-PP-332 is an ERR agonist. Cardarine (GW-501516) is a PPAR-delta agonist. They operate through completely different receptor systems and transcriptional pathways. Some vendors mislabel SLU-PP-332 as a PPAR-delta agonist, which is incorrect and indicates poor quality control.
Does SLU-PP-332 suppress appetite?
No. Unlike GLP-1 receptor agonists, SLU-PP-332 does not suppress appetite. The fat loss observed in animal studies occurred entirely through increased energy expenditure and metabolic reprogramming without changes in food intake.
How long does SLU PP 322 take to work in research models?
Metabolic effects appear within days of administration in animal models. Body weight changes become significant over 2 to 4 weeks. Mitochondrial adaptations may require longer exposure periods depending on the endpoint measured.
Can SLU-PP-332 be combined with other research compounds?
Some researchers combine SLU-PP-332 with AMPK activators like MOTS-C or AICAR for synergistic metabolic effects. Co-administration studies should validate compatibility and dosing interactions in your specific model.
Where to buy SLU PP 322 peptide for research?
Pure Peptide Factory stocks research-grade SLU-PP-332 with domestic cold-chain shipping and batch-specific HPLC and mass spectrometry documentation. Orders placed before 2 PM EST ship same-day and arrive within 1 to 3 business days. You must agree to research-use-only terms at checkout.
How should SLU-PP-332 be stored?
Lyophilized powder stores at -20°C for up to 24 months protected from light. Reconstituted solution stores at 2 to 8°C for up to 14 days under sterile conditions. Do not freeze reconstituted solution. Protect from light at all stages.
What is the purity of your SLU-PP-332?
Our current batch tests at 98.7% purity by HPLC with structural confirmation by mass spectrometry. The Certificate of Analysis is available for download with your order.
Order SLU PP 322 for Research
Secure Checkout
-
Credit card, cryptocurrency, or wire transfer
-
Same-day dispatch for orders placed before 2 PM EST
-
Cold-chain packaging with phase-change cooling
-
Discreet labeling and full tracking
Institutional Accounts
Net-30 terms and purchase order acceptance available for universities and pharmaceutical companies. Contact us for bulk pricing on 50 vials or more.
Add to cart and get batch-verified SLU-PP-332 delivered to your lab with the documentation your protocol demands.
